Proniras Corporation Analysis: $11M Raised
What is Proniras Corporation?
Proniras Corporation is a clinical-stage biotechnology company developing small-molecule therapeutics for substance use and specialty CNS disorders. Its lead program PRN-001-01 (tezampanel) is in clinical development for opioid withdrawal and related addiction disorders. The company was founded in 2018 by Accelerator Life Science Partners and has secured a National Institute on Drug Abuse grant to advance its Phase 1 study.
Location
Seattle, United States
Employees
1-10
Founded
2018
Funding Status
Series B
Product Features & Capabilities
- Tezampanel for opioid withdrawal treatment
- Clinical development of small-molecule therapeutics for CNS disorders
Use Cases
Treat opioid withdrawal symptoms in patients undergoing addiction therapy; Support clinical trials for tezampanel in Phase 1 studies; Develop treatments for related CNS disorders including seizure disorders
Other Considerations
Secured NIDA grant to support Phase 1 study; Raised Series B financing in 2024; Founded by Accelerator Life Science Partners; Based in Seattle, WA, US
See something that needs updating? Suggest edits to this profile.